Acola Corp. Announces New Scientific Advisor, Bruce A. Aronow, Ph.D., Head of Genome Research, Children's Hospital Medical Center, Cincinnati, Ohio.Business Editors & Health/Medical Writers HOUSTON--(BUSINESS WIRE)--Nov. 29, 2001 Acola Corp., a Delaware corporation A Delaware corporation is a corporation chartered in the U.S. state of Delaware. Delaware is well known as a corporate haven, and thus, over 50% of US publicly-traded corporations and 58% of the Fortune 500 companies are incorporated in the state. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ACAC ACAC Acetylacetone ACAC Association of College Admissions Counselors ACAC Arkansas Community Arts Cooperative ACAC Alberta Colleges Athletics Conference (Canada) ACAC Air-Cooled Air Cooler (aviation) ) ("Acola"), announced today that Dr. Bruce A. Aronow has agreed to join the Acola team as a scientific advisor. Dr. Aronow is head of genome research, Children's Hospital Medical Center, Cincinnati and a member of the Human Genome Project. Dr. Aronow has researched ANVIRZEL(TM) over the past two years and will coordinate genomic research for Acola with other leading scientists at special facilities, under arrangements currently being made by Acola. For more information, visit our Web site at www.acolacorp.com. According to Acola's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Robert B. Dillon, "Acola Corp. is very pleased to have a scientist of Dr. Aronow's distinction and reputation on board the Acola team. We are excited about working with Dr. Aronow over the next several years." Dr. Aronow will assist Acola with all aspects of research and development and work with management in structuring Acola's testing and development plans. This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements made by Acola or on its behalf. These forward-looking statements are not historical facts, but reflect Acola's current expectations, estimates and projections. All statements contained in the press release which address future operating performance, events or developments that are expected to occur in the future (including statements relating to earnings expectations, sales of assets, or statements expressing general optimism about future operating results) are forward-looking statements. Although Acola believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. Important factors that could cause actual results to differ materially from those in the forward-looking statements herein include success in marketing Anvirzel(TM) in Mexico, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of Anvirzel(TM) in the United States, development of Acola's market in Mexico, and conditions of the capital markets and equity markets during the periods covered by the forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion